Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production  by Baraz, Lea et al.
Human immunode¢ciency virus type 1 Vif-derived peptides inhibit the
viral protease and arrest virus production
Lea Baraz1;a, Assaf Friedlerc, Immanuel Blumenzweiga, Orna Nussinuva, Nissim Chena,
Michael Steinitzb, Chaim Gilonc, Moshe Kotlera;*
aDepartment of Molecular Genetics, The Hebrew University-Hadassah Medical School, Jerusalem 91010, Israel
bDepartment of Pathology, The Hebrew University-Hadassah Medical School, Jerusalem, Israel
cDepartment of Organic Chemistry, The Hebrew University, Jerusalem, Israel
Received 20 October 1998; received in revised form 24 November 1998
Abstract Human immunodeficiency virus type 1 (HIV-1) Vif
protein is required for productive HIV-1 infection of peripheral
blood lymphocytes and macrophages in cell culture and for
pathogenesis in the SCID-hu mouse model of HIV-1 infection.
Vif inhibits the viral protease (PR)-dependent autoprocessing of
truncated HIV-1 Gag-Pol precursors expressed in bacterial cells
and efficiently inhibits the PR-mediated hydrolysis of peptides in
cell-free systems. The obstructive activity of Vif has been
assigned to the 92 amino acids residing at its NP-terminus
(N-Vif). To determine the minimal Vif sequence required to
inhibit PR, we synthesized overlapping peptides derived from
N-Vif. These peptides were then assessed, using two in vitro and
two in vivo systems: (i) inhibition of purified PR, (ii) binding of
PR, (iii) inhibition of the autoprocessing of the Gag-Pol
polyprotein expressed by a vaccinia virus vector, and (iv)
inhibition of mature virus production in human cells. The
peptides derived from two regions of N-Vif encompassing
residues Tyr-30^Val-65 and Asp-78^Val-98, inhibited PR
activity in both the in vitro and the in vivo assays. Thus, these
peptides can be used as lead compounds to design new PR
inhibitors.
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1. Introduction
Vif (virion infectivity factor), one of the auxiliary proteins
expressed by human immunode¢ciency virus type 1 (HIV-1),
is conserved among HIV-1 isolates and in lentiviruses [1^4]. In
the absence of Vif, HIV-1-infected non-permissive cells pro-
duce non-infectious virions [5^10] that penetrate cells but are
unable to e⁄ciently synthesize viral DNA [10^12]. Vif-de¢-
cient particles can e¡ectively initiate virion production only
in certain lymphoid cell lines, such as SupT 1, which are able
to complement Vif function(s) [13,14]. Vif-de¢cient viruses
which are produced by peripheral blood lymphocytes (PBL)
or macrophages, the two major HIV-1 target cells in the hu-
man body, have aberrations in core protein composition [6,14]
and in core morphology [6,15]. Virions carrying partially
processed Gag and Gag-Pol precursors display attenuated in-
fectivity [14], suggesting that Vif ensures the proper processing
and assembly of viral precursors required for the production
of infectious virions. Support for this notion was recently
provided by Bouyac et al. [16], who demonstrated that se-
quences at the half CP-terminus of Vif (C-Vif) interact with
two regions of the HIV-1 Gag protein.
The retroviral Gag and Gag-Pol polyproteins are translated
from mRNA that is indistinguishable from the full-length
genomic RNA found in virions. The autoprocessing of Gag
and Gag-Pol precursors into structural and catalytic proteins
is carried out by viral protease (PR) [17,18]. The proteolytic
activity of PR is essential to the production of infectious vi-
ruses [17^19]. Thus, PR has been the target for several anti-
viral compounds, such as saquinavir, indinavir, ritonavir and
nel¢navir, which show therapeutic promise [20].
The HIV-1 PR, enzymatically active as part of the viral
precursor [21^23], is tightly regulated: overexpression [24],
expression of PR monomers in tandem [25^27], expression
of mutated overactivated enzyme [28], or activation of PR
prior to virus assembly [27] prevents the generation of infec-
tious particles. Thus, Vif appears to act in non-permissive cells
as a proteolytic regulator directing the initiation of precursor
processing to the right location, at the correct time, to assure
the production of mature virions. Our previous results [29]
clearly show that Vif and its NP-terminus (N-Vif; i.e. Vif
1^92), but not C-Vif (i.e. Vif 93^192), inhibit the autoprocess-
ing of truncated Gag-Pol polyproteins expressed in bacteria
and that Vif and N-Vif inhibit the hydrolysis of synthetic
peptides in vitro [29]. In the present study we performed a
peptide mapping of the N-Vif and revealed that the active
domains in Vif encompassing residues Tyr-30^Tyr-44 and
Asp-78^Val-98. Our results show that peptides derived from
these regions inhibited PR activity in both the in vitro and in
vivo assays and reduced infectious virus production by HIV-
1-infected cells. Thus, we suggest that peptides derived from
these regions can be used as lead compound to design new PR
inhibitors.
2. Materials and methods
2.1. Cells and viruses
Hut 78 cells and PBL were maintained in RPMI 1640 and HeLa
CD4+ cells were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM). Media were supplemented with 10% fetal calf serum, anti-
biotics (penicillin and streptomycin), and 2 mM glutamine. PBL were
stimulated with 1 Wg/ml of phytohemagglutinin (PHA) 24 h before
infection. HIV-1IIIB was kindly supplied by Dr. Wainberg (Lady Da-
vis Institute, Montreal, Canada) and the vaccinia vector (vVK-1),
which expresses the entire HIV-1 gag and pol genes [30], was obtained
from Dr. B. Moss (Laboratory of Viral Diseases, NIAID, NIH, Be-
thesda, MD, USA).
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2.2. Titration of HIV-1 on HeLa CD4+ cells
HeLa CD4+ cells plated on 96 wells were infected with 20 Wl of
clari¢ed medium harvested from HIV-1-infected Hut 78 cells. Follow-
ing absorption for 60 min at 37‡C, the virus was replaced with fresh
medium. To determine the number of LacZ-positive cells, cultures
were ¢xed with 2% formaldehyde and stained with X-Gal as previ-
ously described [31].
2.3. Analysis of viral proteins
Twenty four hours post infection with vVK-1 at a multiplicity of
infection (MOI) of 1, cells were pelleted at 2000 rpm for 5 min. The
supernatants were cleared of cell debris by spinning at 10 000Ug for
10 min, before centrifugation for 45 min at 100 000Ug in a Beckman
centrifuge (Ti-50.2 rotor) through a 20% sucrose cushion. Cellular and
particle pellets were dissolved in Laemmli bu¡er, separated by electro-
phoresis before Western blotting. Blots were incubated with mono-
clonal antibody against HIV-1 CA (contributed by Dr. K. Steimer
and obtained through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH) and visualized by en-
hanced chemiluminescence (Sigma). In each experiment equal num-
bers of vVK-1-infected cells were used to prepare lysates.
Five days post infection of Hut 78 cells with HIV-1IIIB at an MOI
of 0.5, cells were washed and incubated for 1 h with a mixture of 1 ml
of RPMI 1640 medium and 0.5 ml water containing 1 mg peptide.
Following incubation, cell suspensions were diluted with RPMI 1640
medium to a ¢nal concentration of 60 WM peptide and incubated for
an additional 48 h. Cells and viruses were harvested and analyzed as
described above.
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Fig. 1. A: Sequence of peptides derived from the NP-terminus of the HIV-1 Vif protein (upper row) that were synthesized and tested in this
study. B: Screening of Vif-derived peptides for inhibition of PR-mediated hydrolysis of synthetic peptide substrate in vitro. Hydrolysis of de-
capeptide substrate by HIV-1 PR (0.5 WM) in the presence of Vif-derived peptides (1 mM), pepstatin A or Ro31-8959 (0.1 mM), HIV-1 Tat-de-
rived peptide Cys-Gly-Arg-Lys-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ala-His-Gln-Asn (1 mM) was analyzed by HPLC (peptide 42 overlapped
with the substrate peak and could therefore not be assayed). The cleavage products of substrate in the standard reaction without inhibitors
(36%) is taken as 100%. C: Dose-dependent inhibition of PR activity by Vif-derived peptides. Reactions were carried out with increasing con-
centrations of Vif-derived peptides in standard reaction mixtures where the uninhibited reactions (25% cleavage) were taken as 100%. The data
in B and C are from one of three experiments with similar results.
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2.4. Peptides
Peptides were synthesized according to the SPPS method, using an
Applied Biosystems peptide synthesizer, model 433A on Rink amide
resin (loading 0.5 mmol/g) by standard Fmoc chemistry. They were
cleaved from the resin with tri£uoroacetic acid (TFA) containing 5%
anisole as a scavenger, precipitated from cold ether, dissolved in water
and lyophilized. Crude peptides were analyzed by reverse-phase
HPLC (C3 column 5^60% acetonitrile: water gradient containing
0.1% TFA, 45 min) and characterized by TOF-MS and amino acid
analysis.
2.5. Synthetic peptide cleavage assay
The standard conditions of the assay were essentially as described
previously [32,33]. A standard reaction mixture (10 Wl) contained
1 mM of the natural MA/CA junction decapeptide (Val-Ser-Gln-
Asn-Tyr-Pro-Ile-Val-Gln-Asn), 0.5 WM puri¢ed PR [22] and 0.1 M
NaCl in 50 mM sodium phosphate bu¡er (pH 5.5). Mixtures were
incubated at 37‡C and the reaction was terminated by the addition of
90 Wl guanidine-HCl (pH 8.0) to a ¢nal concentration of 6 M. Ali-
quots of 80 Wl were analyzed by reverse phase HPLC (Vydac C18
column; 0^40% acetonitrile:water gradient containing 0.1% TFA)
and percent cleavage was calculated as the ratio between the peak
areas corresponding to the cleavage product (P) and uncleaved sub-
strate (S).
% Cleavage  P=P SU100
The cleavage of substrate obtained in standard reaction mixtures
without inhibitors was taken as total uninhibited protease activity,
represented by 100% cleavage.
2.6. Vif-derived peptide/PR binding assay
Each well of a 96 microwell ELISA plate (M-129B, Dynatech) was
coated for 18 h at 4‡C with 200 Wl of a solution containing 12 WM
peptides in 100 mM Tris-HCl (pH 8.8). This amount of peptide was
su⁄cient to saturate the wells. In order to stabilize peptide 7, dithio-
threitol (1 mM) was added to all solutions containing this peptide.
The wells were aspirated, incubated with low fat milk for 1 h and
washed with PBS containing 0.05% Tween 20. A volume of 200 Wl
containing 20 nM PR in 0.1 M NaCl and 50 mM sodium phosphate
bu¡er (pH 7.4) was then added to each well and the microplates were
incubated for 2 h at room temperature.
In the competitive binding experiments, 20 nM of PR (in 200 Wl of
100 mM Tris-HCl pH 8.8) was incubated for 18 h at 4‡C with 14 nM
Ro31-8959, with 60 WM of each peptide, or with 25 WM of peptide 4
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before being added to the coated wells. The plates were extensively
washed and PR binding was determined using rabbit anti-PR serum
and alkaline phosphatase-conjugated goat anti-rabbit IgG diluted
1:1000 (Sigma) as secondary antibody. The wells were developed by
adding substrate p-nitrophenyl phosphate (Sigma) and bound PR was
quanti¢ed with an ELISA reader (Dynatech MR5000) at 405 nm.
3. Results
3.1. Vif-derived peptides inhibit PR activity
To determine which active Vif domain(s) is capable of in-
hibiting PR, a set of partially overlapping peptides was syn-
thesized, based on the sequence of HIV-1 BH10 Vif [34] (Fig.
1A). Inhibition of HIV-1 PR activity by Vif-derived peptides
was determined by the reduction of cleavage product (P) for-
mation in a standard reaction mixture in comparison with
uninhibited PR. Screening of crude peptides (70^90% purity)
for PR inhibition revealed that peptides derived from two
regions of Vif (30^65 and 78^98), namely peptides 4, 6 and
7, inhibited proteolysis (Fig. 1B). The IC50 of peptide 4 was in
the range of 230^250 WM, whereas the IC50 values of peptides
6 and 7 were in the order of 110 and 25 WM, respectively (Fig.
1C). The 11 amino acids long peptide 7 also inhibited the
cleavage of the £uorogenic substrate Arg-Glu(EDANS)-Ser-
Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg (50 WM) by
HIV-1 PR and the IC50 value was 3.3 WM (results not shown).
Peptides 41 and 43, each composed of 15 amino acid residues,
were less active than peptide 4 (Fig. 1B). Overlapping peptides
6 and 7, containing the Arg-Lys-Lys-Arg motif, proved to be
e⁄cient inhibitors.
3.2. Binding of HIV-1 PR to Vif-derived peptides
The interaction of Vif-derived peptides with PR was tested
by ELISA, using rabbit anti-PR (prepared by immunizing
rabbits with puri¢ed PR expressed in bacteria). Microtiter
plates were coated with peptides and PR was then added
with or without preincubation with the cognate peptide. Pep-
tides 4, 41, 42, 43, 6, and 7, but not peptide 3, signi¢cantly
bound PR. Binding of PR to the absorbed peptides, except
peptide 42, was speci¢cally inhibited by preincubation with
the cognate peptides (Fig. 2A). There was no speci¢c interac-
tion between PR and peptides 2 and 44 (results not shown).
The concentration of PR required to saturate the absorbed
peptides was 6^10 nM (Fig. 2B). To determine the concentra-
tion of peptide required to block binding of PR to the ab-
sorbed peptide, the enzyme (10 nM) was preincubated with
increasing concentrations of cognate peptide. Binding of PR
to peptides 4, 41, 43, 6 and 7 was speci¢c, as preincubation of
the enzyme with each of the cognate peptides resulted in dose-
dependent inhibition (Fig. 2C). In contrast, the binding of PR
to peptide 42 was not a¡ected, indicating again that the in-
teraction was non-speci¢c.
The speci¢c PR inhibitor Ro31-8959 [35], which blocks the
active site of PR, was used as a control. Preincubation of PR
with the inhibitor reduced the binding of the enzyme to Vif-
derived peptides (Fig. 2A), showing the speci¢city of the re-
action.
3.3. Inhibition of processing of Gag-Pol precursors expressed
by vVK-1 in human cells
We analyzed the e¡ect of Vif-derived peptides on the proc-
essing of HIV-1 precursors expressed in human cells infected
with vVK-1 [30]. Infection of human T-cell line Hut 78 and
PHA-stimulated PBL with vVK-1 resulted in high levels of
Gag protein production within 24 h, allowing the natural
PR-mediated processing of viral precursors and the release
of virus-like particles. As shown in Fig. 3, vVK-1-infected
cells and the particles exported to the culture medium by these
cells contained completely or partially processed Gag pro-
teins, namely p55Gag, MA-CA p41 and CA p24, as determined
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Fig. 2. A: Competitive binding of puri¢ed PR to Vif-derived pepti-
des, determined by ELISA. Binding of PR (20 nM) to the Vif-de-
rived peptides (black bars), binding with competing peptide 4
(25 WM) and peptides 3, 41, 42, 43, 6 and 7 (60 WM) (white bars),
or Ro31-8959 (14 nM) (gray bars). B: Dose-dependent binding of
PR to Vif-derived peptides. The assay was carried out as described
in A with increasing concentrations of PR. C: Competitive inhibi-
tion of PR binding by Vif-derived peptides. 10 nM PR was preincu-
bated for 18 h in 200 Wl with increasing concentrations of the cog-
nate peptides before adding the mixture to the peptide-coated
microwells. Black bars: without peptide; vertically hatched bars:
0.6 WM; gray bars: 6 WM; white bars: 30 WM for all peptides, while
the concentrations of peptide 4 were 0, 0.25, 2.5 and 12.5 WM, re-
spectively.
L. Baraz et al./FEBS Letters 441 (1998) 419^426422
by Western blot. vVK-1-infected Hut 78 cells incubated for
24 h with peptides 42 and 43 contained the same HIV-1 poly-
proteins present in the control vVK-1-infected cells. However,
cells incubated with peptides 41, 6 and 7 contained the un-
processed MA-CA and p55Gag polyproteins and only small
amounts of mature CA protein (Fig. 3A). The ratio of
p55Gag to MA-CA p41 proteins in cells treated with peptides
6 and 7 is higher than the p55Gag/p41 ratio in vVK-1 cells,
suggesting that these peptides, as well as peptide 41, inhibit
the autoprocessing of viral precursors.
Production and autoprocessing of HIV-1 precursors in
vVK-1-infected PBL were not dramatically a¡ected by the
Vif-derived peptides (Fig. 3C). However, particles released
from PBL (Fig. 3D) and from Hut 78 cells (Fig. 3B) following
treatment with peptides 41, 6 and 7, contained mostly unpro-
cessed Gag polyproteins and only minor fractions of mature
CA protein. Peptide 43 exerted an e¡ect similar to that of
peptides 41, 6, and 7 on particles released from PBL (Fig.
3D), but did not a¡ect, or only slightly a¡ected, the particles
released from Hut 78 cells. These results clearly demonstrate
that peptides derived from residues Tyr-30^Tyr-44 and Asp-
78^Val-98 inhibit the processing of the viral precursors ex-
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Fig. 4. Inhibition of HIV-1 maturation by Vif-derived peptides. Hut 78 cells (A) and extracellular virions (B) were harvested as described in
Fig. 3 and analyzed by Western blotting using monoclonal anti-CA antibody.
Fig. 3. Inhibition of autoprocessing and of virus-like particle maturation by Vif-derived peptides. Hut 78 cells (A and B), and PBL (C and D)
were infected with vVK-1 expressing HIV-1 Gag-Pol and cultured in the presence of the respective Vif-derived peptides. Cells (A and C) and
extracellular virus-like particles (B and D) were harvested 24 h post infection and analyzed by Western blotting for the presence of Gag-con-
taining proteins, using monoclonal anti-CA antibody. Incubation of the cells with 60 WM of the peptides did not cause any cytotoxic e¡ect, as
determined by trypan blue staining. The pT5 lanes contain a bacterial lysate from cells expressing HIV-1 MA to PR or CA to NC [21,22,29].
The mobility of p55Gag, p41 including MA and CA, and p24 CA is indicated to the left of each autoradiogram.
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pressed in human cells. Di¡erences in penetration and stability
of the linear Vif-derived peptides may have caused the various
e¡ects on viral precursor processing observed in the cells types
used. The inhibition of viral precursors autoprocessing exerted
by peptides 41, 6 and 7 cannot account for their toxicity on
the host cells because similar amounts of viral proteins are
accumulated in treated and untreated cells (Fig. 3A,C).
3.4. Vif-derived peptides reduce the production of infectious
virus
The e¡ect of Vif-derived peptides on HIV-1 maturation was
assessed by incubating Hut 78 cells with the peptides for 48 h,
5 days post infection with HIV-1IIIB. Treatment of cells with
peptides 42 and 43 did not in£uence the autoprocessing of
Gag polyproteins, as determined by Western blot of the cell
lysates (Fig. 4A). On the other hand, peptides 41, 6 and 7 halt
the processing of the Gag precursor in the treated cells as p41
MA-CA and CA-p2 (p26) fusion proteins are clearly detected
in the Western blot. However, the cleavage inhibition medi-
ated by Vif-derived peptides was not as e⁄cient as the inhib-
ition by Ro31-8959 since unprocessed p55Gag protein was not
observed in these cells (Fig. 4A). Unlike Ro31-8959 treatment
which allows the release of particles with uncleaved Gag pro-
teins, peptides 41, 6 and 7, but not peptides 42 and 43, re-
duced the release of particles containing CA into the culture
medium (Fig. 4B). It is possible that the partial inhibition of
polyprotein processing reduced or prevented the release of
sedimented particles into the medium.
The reduced amounts of p24 CA antigen in the culture
media following a 48 h treatment with peptides 41, 6 and 7
(Fig. 4) correlates with the decreased production of infectious
virions as titered on HeLa CD4+ cells [31]. Peptides 41, 6 and
7 reduced the titer of infectious virus by 90, 96 and 97%,
respectively (Table 1). Thus, we suggest that these peptides
interfere with the autoprocessing of viral precursors in human
cells infected with HIV-1 and cause a signi¢cant reduction in
the number of infectious virions released from the HIV-1-in-
fected cells.
Two approaches were taken to determine whether pro-
longed treatment by Vif-derived peptides reduces virus pro-
duction. Five days post infection Hut 78 cells were cultured
for 9 days in the presence of Vif-derived peptides and the
amount of p24 CA antigen was determined. Fig. 5A shows
that prolonged treatment of HIV-1IIIB chronically infected
Hut 78 cells with peptides 41, 6 and 7, but not with peptide
42 and 43, caused a reduction in the total amount of particu-
lated and soluble p24 antigen present in the culture media.
Similarly, treatment of newly infected Hut 78 cultures (at an
HIV-1IIIB MOI of 0.1) with peptides 41, 6, and 7 for 9 days
reduced the release of CA antigen in the media, indicating less
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Fig. 5. Reduction of virus production followed by treatment with
Vif derived peptides. A: Chronically infected Hut 78 cells (7.5U104
cells/well) 5 days post infection were cultured for 9 days in a 96 mi-
crowell plate in 200 Wl of RPMI 1640 containing 60 WM of Vif-de-
rived peptides. Half of the culture medium was replaced daily with
fresh medium containing 30 WM of the tested peptide. Aliquots
(100 Wl) of cell-free medium removed at the indicated days were
quanti¢ed for p24 CA antigen, using a Vironostika HIV-1 Antigen
Microelisa System (Organon Teknika, USA). B: Newly infected cells
were treated as described in A and p24 CA antigen was quanti¢ed
after 9 days of treatment.
Table 1
Infectivity of virus released from HIV-1-infected Hut 78 cells treated
Treatment No. of LacZ-positive cells Virus titer (IU/ml)b Reduction of virus titer (%)
undiluteda 1:10 dilution
None (control) 1068 96 50 700 ^
Peptide 41 137 6 4 925 91
Peptide 42 1120 81 48 250 5
Peptide 43 946 73 41 900 7
Peptide 6 63 2 2 075 96
Peptide 7 52 1 1 550 98
Ro31-8959 167 18 8 657 83
a20 Wl of medium undiluted and 10-fold diluted harvested from HIV-1-infected Hut 78 cells treated with Vif-derived peptides (60 WM) or Ro31-8959
(100 nM) was used to infect HeLa CD4+ cells. The number of LacZ-positive cells is the average obtained from duplicate wells.
bIU = infectious units.
Representative data of three independent experiments are shown.
L. Baraz et al./FEBS Letters 441 (1998) 419^426424
virus propagation in these cells (Fig. 5B). The inhibition of
particle release is certainly not due to cytotoxicity induced by
the Vif-derived peptides, because no di¡erence in proliferation
between cells treated with the peptides (up to 90 WM) and
untreated controls cultured over a period of 9 days was found.
4. Discussion
Previously we demonstrated that Vif and N-Vif, but not C-
Vif, inhibit the autoprocessing of truncated Gag-Pol polypro-
teins expressed in bacterial cells and inhibit the hydrolysis of
synthetic peptide by puri¢ed PR in cell-free systems [29]. In an
attempt to determine the minimal Vif sequence required to
inhibit PR, we synthesized overlapping peptides derived
from N-Vif and assessed them using in vitro and in vivo
systems. The cell-free systems described here, namely inhibi-
tion and binding of PR by Vif-derived peptides, provide ex-
treme £exibility to optimize reactions in order to observe, and
potentially enhance, any subtle e¡ects of Vif on protease.
Peptides 4, 41, 6 and 7 derived from two stretches of N-Vif,
encompassing residues Tyr-30^Val-65 and Asp-78^Val-98, in-
hibit PR activity and bind PR in cell-free systems. Peptides 41,
6, and 7 (peptide 4 is too large to penetrate the cells) suppress
the autoprocessing of viral precursors expressed by vVK-1
and HIV-1 in human cells and inhibit the production of in-
fectious virus. It is interesting to note that peptide 4, which
tightly binds and inhibits PR, includes sequences that are
conserved in HIV-2 and in other non-human lentiviruses [3],
whereas domains including peptides 6 and 7 (amino acids 87^
94) are antigenic [36] and relatively conserved among long-
term AIDS survivors [37]. It is conceivable that although both
regions are sequentially remote, they are spatially close and
could, therefore, form an active site. Resolution of the three-
dimensional structure of the Vif:PR complex and determina-
tion of the synergistic activity of the peptides might help to
clarify the mode of action of Vif.
The activity of peptides 41, 6 and 7 di¡ers from that of the
PR inhibitor Ro31-8959. Ro31-8959 inhibits the processing of
viral precursors in HIV-1-infected cells but allows the release
of non-infectious particles containing unprocessed Gag poly-
protein to the culture medium [35]. Inhibition of viral precur-
sor processing was also observed in the same cells treated with
the Vif-derived peptides, although p55Gag undergoes cleavage
(Fig. 4). These cells released reduced amounts of p24 CA
antigen to the medium, but unprocessed viral proteins were
not detected in pellets prepared from these treated cells. The
partial inhibition of viral precursor autoprocessing caused by
peptides 41, 6 and 7 in the cells (Fig. 4A) may be su⁄cient to
interfere with assembly and/or release of particles, as shown
previously for other PR inhibitors [38^40]. Alternatively, these
particles may be unstable and/or morphologically deformed,
and therefore did not pellet through the sucrose cushions.
Our ¢nding that Vif-derived peptides inhibit both the auto-
processing of Gag and Gag-Pol polyproteins in eukaryotic
cells and the hydrolysis of synthetic peptides in vitro supports
the supposition that Vif is responsible for the delay in PR
activation, which lasts until assembly of the particles has tak-
en place [29]. This delay is advantageous to both the virus and
its host cell for the following reasons: (i) it ensures migration
of viral structural components and catalytic enzymes to the
site of virion assembly at an appropriate molar ratio; (ii) it
hinders PR digestion of cellular proteins; and (iii) it prevents
reverse transcriptase and integrase from acting on cellular
RNA and causing unregulated gene ampli¢cation. Since PR
is active as part of the Gag-Pol precursor [21^23], the delay
should be operative at a post-translational stage. Moreover, it
is most likely that the inhibition of PR is reversible, enabling
the processing of viral precursors during particle assembly.
Regions in the CP-terminus of Vif are responsible for its
binding to the inner surface of the outer cell membrane
([41], but see [42]). The same basic region of C-Vif is involved
in binding two separate Gag domains, namely the NC and the
MA/CA junction [16]. Our results indicate that peptides 41, 6
and 7, located in the N-Vif region, interact with PR. It is
possible that all three binding sites play a pivotal role in the
regulation of Gag and Gag-Pol processing. We suggest that
regions of N-Vif inhibit the activation of PR when it is part of
Gag-Pol. Upon arrival at the assembly site, the free CP region
of Vif interacts with the component(s) of the plasma mem-
brane, allowing the initiation of processing. This is followed
by the cleavage of Gag polyproteins, ¢rst in the SP-1/NC and
later at the MA/CA junctions. As a result, the interaction
between the Vif molecules and Gag is abolished, enabling
the shift of Vif from the viral proteins to the outer cell mem-
brane. Alternatively, the release of Vif molecules from all
three Vif binding sites ensures appropriate processing. In the
absence of the basic CP region of Vif, the N-Vif-derived pep-
tides remain bound to PR, and arrest the processing of the
viral precursors. This model is consistent with the low levels
of Vif present in virions [43] and with the ¢nding that auto-
processing of viral precursors takes place at the plasma mem-
brane where Vif is associated [38,44]. In transformed cells,
where Vif is not essential for production of infectious virions
(permissive cells), cellular protease inhibitor(s) might comple-
ment this Vif function.
This report, which describes a peptide mapping of N-Vif,
clearly shows that three out of 11 peptides derived from N-Vif
bind and inhibit HIV-1 PR in vitro, a¡ect the processing of
viral precursors in human cells and reduce the production of
viral particles from infected cells. Thus, Vif-derived peptides
provide an attractive potential therapeutic agent for inhibition
of HIV-1 PR during infection in humans. The serious limita-
tions of linear peptides as therapeutic agents are attributable
to their susceptibility to proteolysis, poor bioavailability, un-
favorable pharmacokinetics and rapid clearance. Conversion
of the linear bioactive peptides described in this study into
peptidomimetics (e.g. backbone cyclic peptides) is now under
way in our laboratories.
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